---
$id: https://graph.org.ai/products/commodity/51131741
$type: Product
source: UNSPSC
code: "51131741"
title: "Trifenagrel"
class: "51131700"
classTitle: "Thrombolytic drugs and platelet aggregation inhibitors"
family: "51130000"
familyTitle: "Hematolic drugs"
segment: "51000000"
segmentTitle: "Pharmaceutical Products incl. Contraceptives and Vaccines"


---

# Trifenagrel

**UNSPSC Code**: 51131741
**Class**: [Thrombolytic drugs and platelet aggregation inhibitors](Thrombolytic drugs and platelet aggregation inhibitors.mdx)
**Family**: [Hematolic drugs](../Hematolic drugs.mdx)
**Segment**: [Pharmaceutical Products incl. Contraceptives and Vaccines](../../Pharmaceutical Products incl. Contraceptives and Vaccines.mdx)

This classification denotes an antiplatelet agent with the molecular formula C25H25N3O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 59X5ME2O06, chemically known as 2-(o-(2-(dimethylamino)ethoxy)phenyl)-4,5-diphenylimidazole but generally known as trifenagrel, which bears US NIH Compound Identifier 72164. European Medicines Agency schedules Trifenagrel in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB11282MIG. The term TRIFENAGREL is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 39, No. 5, 1985, List 25). TRIFENAGREL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule trifenagrel under HS 29332990 and SITC 51573. As of Q4 2014, TRIFENAGREL remains the US FDA Preferred Term for this commodity. Trifenagrel bears US NLM identifiers UMLS ID C0637269 and NCI Concept Code C76406. SMILES: O(C1C(C2[NH]C(C(N2)C2CCCCC2)C2CCCCC2)CCCC1)CCN(C)C.

